Recently Featured

PMV Pharmaceuticals Reports Promising Phase I Results for Rezatapopt in Advanced Solid Tumors

February 28, 2026
PMV Pharmaceuticals has announced significant findings from the Phase I, first-in-human segment of the ongoing Phase I/II PYNNACLE study, which evaluates the small molecule therapy rezatapopt in patients with advanced solid tumors that carry a TP53 Y220C mutation. The results, published in the New England Journal of Medicine, detail safety and efficacy data from 77…

DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case

February 28, 2026
The U.S. Solicitor General has urged the Supreme Court to reverse a recent decision regarding the Hikma ‘skinny label’ case, a ruling that could significantly impact the generic drug market. The Solicitor General argues that this decision threatens to undermine a crucial pathway that allows for the expedited entry of new generic drugs, which is…

Cigna Acquires CarepathRx, Expanding Control Over Prescription Drug Flow

February 28, 2026
Cigna has acquired CarepathRx, a prominent pharmacy that supplies prescription drugs to nearly 10% of U.S. hospitals. This strategic acquisition, revealed through a review of Cigna’s financial filings by STAT, marks a significant move in the company’s ongoing efforts to enhance its influence over the pharmaceutical supply chain within the U.S. health care system. The…

Pharma Expands Global Footprint to Enhance Clinical Research Operations

February 27, 2026
Pharmaceutical organizations are increasingly expanding their clinical trial operations on a global scale, a strategic move driven by the need to support evolving portfolios and adapt to shifting geopolitical landscapes. This trend reflects a broader industry response to the complexities of drug development, where access to diverse patient populations and regulatory environments is becoming paramount.…

Ongoing Cases